U.S. Capital Wealth Advisors LLC cut its stake in McKesson Corporation (NYSE:MCK - Free Report) by 31.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,918 shares of the company's stock after selling 869 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in McKesson were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of the stock. Capital A Wealth Management LLC bought a new position in McKesson during the fourth quarter valued at about $26,000. Millstone Evans Group LLC bought a new position in McKesson during the fourth quarter valued at about $28,000. Atala Financial Inc bought a new position in McKesson during the fourth quarter valued at about $34,000. Graney & King LLC bought a new position in McKesson during the fourth quarter valued at about $38,000. Finally, CoreFirst Bank & Trust bought a new position in McKesson during the fourth quarter valued at about $67,000. 85.07% of the stock is owned by institutional investors and hedge funds.
Insider Activity at McKesson
In other news, CFO Britt J. Vitalone sold 1,878 shares of McKesson stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $717.91, for a total value of $1,348,234.98. Following the completion of the transaction, the chief financial officer owned 14,028 shares in the company, valued at approximately $10,070,841.48. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 2,891 shares of McKesson stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $712.18, for a total transaction of $2,058,912.38. Following the completion of the transaction, the executive vice president owned 2,544 shares of the company's stock, valued at $1,811,785.92. This trade represents a 53.19% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,117 shares of company stock valued at $23,526,451. Corporate insiders own 0.08% of the company's stock.
McKesson Stock Up 0.4%
MCK stock opened at $727.13 on Thursday. McKesson Corporation has a twelve month low of $464.42 and a twelve month high of $737.89. The company has a market cap of $90.97 billion, a PE ratio of 28.15, a price-to-earnings-growth ratio of 1.44 and a beta of 0.48. The business's 50-day simple moving average is $715.50 and its 200 day simple moving average is $660.30.
McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, beating analysts' consensus estimates of $9.83 by $0.29. The company had revenue of $90.82 billion for the quarter, compared to the consensus estimate of $94 billion. McKesson had a negative return on equity of 201.12% and a net margin of 0.92%. The company's quarterly revenue was up 18.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.18 earnings per share. On average, equities research analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.
McKesson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend was Monday, June 2nd. McKesson's payout ratio is 10.99%.
Analysts Set New Price Targets
A number of equities analysts have recently commented on MCK shares. Evercore ISI lifted their price objective on McKesson from $760.00 to $800.00 and gave the stock an "outperform" rating in a research note on Wednesday. Wells Fargo & Company set a $766.00 price objective on McKesson and gave the stock an "equal weight" rating in a research note on Tuesday, June 3rd. Cfra Research lowered McKesson from a "moderate buy" rating to a "hold" rating in a research note on Friday, April 4th. UBS Group lifted their price objective on McKesson from $708.00 to $805.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Morgan Stanley lifted their price objective on McKesson from $745.00 to $770.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $706.83.
View Our Latest Stock Report on McKesson
McKesson Company Profile
(
Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Articles
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.